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ABSTRACT  
The worldwide rise in prevalence of type 2 diabetes has led to an intense search for the genetic risk factors 
of this disease. In type 2 diabetes and other complex disorders, multiple genetic and environmental factors, 
as well as the interaction between these factors, determine the phenotype. In this review, we summarize 
present knowledge, generated by more than two decades of efforts to dissect the genetic architecture of 
type 2 diabetes. Initial studies were either based on a candidate gene approach or attempted to fine-map 
signals generated from linkage analysis. Despite the detection of multiple genomic regions proposed to be 
linked to type 2 diabetes, subsequent positional fine-mapping of candidates were mostly inconclusive. 
However, the introduction of genome-wide association studies (GWAS), applied on thousands of patients 
and controls, completely changed the field. To date, more than 50 susceptibility loci for type 2 diabetes 
have been detected through the establishment of large research consortia, the application of GWAS on 
intermediary diabetes phenotypes and the use of study samples of different ethnicities. Still, the common 
variants identified in the GWAS era only explain some of the heritability seen for type 2 diabetes. Thus, 
focus is now shifting towards searching also for rare variants using new high-throughput sequencing 
technologies. For genes involved in the genetic predisposition to type 2 diabetes the emerging picture is 
that there are hundreds of different gene variants working in a complex interplay influencing pancreatic 
beta cell function/mass and, only to a lesser extent, insulin action. Several Norwegian studies have 
contributed to the field, extending our understanding of genetic risk factors in type 2 diabetes and in 
diabetes-related phenotypes like obesity and cardiovascular disease. 
 
 
TYPE 2 DIABETES – ETIOLOGY AND 
HERITABILITY 
 
Diabetes is a major global health problem due to drama-
tically increasing prevalence worldwide. Globally, the 
total number of people with diabetes is projected to 
rise from 285 million in 2010 to 439 million in 2030 
corresponding to a predicted increase in prevalence 
from 6.4% to 7.7% (1). The etiology of type 2 diabetes 
is not fully understood, but presumably, type 2 diabe-
tes mainly develops when a diabetogenic lifestyle (i.e. 
excessive caloric intake, inadequate caloric expendi-
ture, obesity) acts in conjugation with a susceptible ge-
notype. Even though there is some disparity regarding 
the reasons for the development of type 2 diabetes, 
most physicians and scientists agree that the major 
independent risk factors for developing the disease are: 
obesity, family history (first-degree relative), ethnicity 
(some ethnic groups have higher prevalence of diabe-
tes), history of previous impaired glucose tolerance or 
impaired fasting glycemia, hypertension or dyslipid-
emia, physical inactivity, history of gestational diabe-
tes, low birth weight as a result of the in utero environ-
ment, polycystic ovarian syndrome leading to insulin 
resistance, and finally, decline in insulin secretion due 
to advancing age (2). 
 The clinical assessment of type 2 diabetes has often 
incorporated genetic information in the form of family 
history. Family information helps to raise clinical 
awareness for an individual patient’s risk of type 2 
diabetes due to the strong heritability of this disease 
and the effect of shared environmental factors between 
close relatives. In contrast to a population risk of 5-
10%, family studies have estimated that the risk for 
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type 2 diabetes among offspring is 3.5-fold and 6-fold 
higher for those with a single diabetic parent and two 
diabetic parents, respectively, compared with offspring 
without parental diabetes (3). Furthermore, the higher 
concordance rate of type 2 diabetes in monozygotic 
versus dizygotic twins and the high prevalence of type 
2 diabetes in specific ethnic groups such as Pima Indi-
ans and Mexican Americans, all lend support to the 
existence of genetic determinants for type 2 diabetes 
(4). Overall, estimates have shown that 30-70% of type 
2 diabetes risk can be ascribed to genetic factors (5). It 
is also evident, for example from a recent study in Fin-
nish families, that type 2 diabetes-related intermediate 
and quantitative traits show substantial heritability (6). 
The patterns of inheritance therefore suggest that type 
2 diabetes and its related traits are both polygenic and 
heterogeneous; hence multiple genes are involved and 
different combinations of genes play a role in different 
subsets of individuals. How many risk genes that exist 
and what their relative contributions are, remains 
somewhat uncertain despite the recent advances in 
dissecting the complex genetic architecture of type 2 
diabetes. The purpose of this paper is to summarize the 
present knowledge of genetic risk factors in type 2 dia-
betes with emphasis on recent Norwegian data. 
 
 
GENETICS OF TYPE 2 DIABETES 
 
Several different approaches have been used in the ex-
ploration of genetic factors involved in type 2 diabetes. 
Progress has generally been guided by technological 
advances in genotyping and sequencing techniques, 
and in statistical handling of data. Also the collection 
of large patient cohorts amendable for genetic studies 
has been crucial. 
 In general, two methods have been used for study-
ing genetic factors involved in human diseases in the 
20th century: the so-called candidate gene approach and 
the linkage analysis approach (7-9). The candidate gene 
approach examines specific genes with a plausible role 
in the disease process. For diabetes, natural candidates 
are genes involved in glucose homeostasis and meta-
bolism. The approach is biased since it assumes that a 
specific gene or locus is associated with disease before 
testing. Genetic variants are identified through focused 
sequencing and further assessed by genotyping in a 
large number of cases and controls. Even though this 
approach has contributed to the identification of 
numerous published associations, only a fraction of the 
associations have been replicated by follow-up studies 
(10,11). 
 The most robust candidate variants reported were 
the E23K variant in the KCNJ11 gene (12-14), the 
P12A variant in the peroxisome proliferator-activated 
receptor-γ (PPARG) gene (15), and common variants 
in the HNF1B and the Wolfram syndrome 1 (WFS1) 
genes (16-18). Notably, rare mutations in all four 
genes cause monogenic forms of diabetes (19-22), and 
two are targets of anti-diabetic therapies. KCNJ11 
encodes a component of the β-cell potassium channel 
that is a target for the sulphonylurea class of drugs, 
and PPARG encodes a transcription factor involved in 
adipocyte differentiation that is a target for the thiazo-
lidinedione class of drugs (4,23). 
 In contrast to the candidate gene approach, linkage 
analysis is not based on assumptions, but identifies 
genes through their genomic position. The rationale is 
that family members sharing a specific phenotype also 
will share chromosomal regions surrounding the gene 
involved. The linkage approach has proved very effec-
tive in the identification of rare variants with large eff-
ects and high penetrance, i.e. those responsible for mo-
nogenic (Mendelian) disorders – including maturity-
onset diabetes of the young (MODY), mitochondrial 
diabetes with deafness, neonatal diabetes and rare 
forms of severe childhood obesity (24-26). 
 However, because the risk for relatives is smaller in 
complex diseases due to the low penetrance of poly-
genic risk variants, the statistical power of the linkage 
approach in studies of polygenic traits is limited (27). 
Even for loci with considerable effects on suscepti-
bility at the population level, the number of families 
needed to offer sound power to detect linkage has 
proven hard to obtain (28). In addition, very few gene-
tic variants with large phenotypic effect appear to be 
present in common complex diseases. Thus, most link-
age studies have, in retrospect, been seriously under-
powered. This probably also explains the lack of repli-
cation of published linkage regions. Moreover, when 
evidence of linkage has been observed, the genomic 
region linked to the trait of interest is often very large. 
Hence the identification of the causal gene or genetic 
variant remains the main challenge. There is one nota-
ble exception: the transcription factor 7-like 2 gene 
(TCF7L2). In 2006, the Icelandic company deCODE 
Genetics identified a common type 2 diabetes suscepti-
bility variant in the TCF7L2 gene region by linkage 
analysis (29). TCF7L2 was a completely unexpected 
type 2 diabetes gene, demonstrating that a genome-
wide approach could uncover previously unknown 
disease pathways (23). 
	 In summary, the methods used successfully to iden-
tify the genes underlying Mendelian inherited diseases 
generally failed in the identification of the genetic 
basis of type 2 diabetes. This suggested that most of 
the genetic contribution to this disorder arises from 
multiple loci with individually small effects (Figure 1). 
The conceptual outline for association studies to 
identify common genetic variants underlying common 
complex diseases is referred to as the common disease/ 
common variant (CD/CV) hypothesis. The major 
assumption behind the CD/CV hypothesis is that since 
the major diseases are common, so are the genetic 
variants that cause them. Moreover, common variants 
with low penetrance and modest risk are not subjected 
to the same negative selection as variants with strong 
phenotypic effect causing Mendelian diseases. Hence, 
the hypothesis states that common diseases are caused  
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Figure 1.  The allelic spectrum of disease – it is all about 
number, frequency and penetrance. The allelic spectrum 
of disease relies on the number of genetic variants, their 
frequency in a population and their penetrance (size of 
phenotypic effect). Linkage studies have proved success-
ful in identifying genetic variants causing rare Mendelian 
disorders, i.e. those caused by low-frequency variants with 
high penetrance. On the genetic level, complex diseases 
are believed to be caused by multiple variants, each con-
ferring only low to modest risk for disease. Modified and 
redrawn from (30). 
 
 
by multiple, high frequency genetic variants conferring 
cumulative incremental effects on disease risk (30,31). 
With these assumptions as a fundament, the next chall-
enge became clear – to survey common genetic vari-
ants in the genomes of a large number of individuals. 
 The breakthrough came in 2006-2007 with the 
successful implementation of genome-wide association 
studies (GWAS). This new approach became possible 
as a result of the completion of the human genome se-
quence in 2001 (32,33), the creation of single nucleo-
tide polymorphisms (SNP) linkage disequilibrium 
(LD) maps by the International HapMap Project (34) 
and great advancements in microarray-based genoty-
ping technology and statistical tools (35). Using SNP-
based arrays and comparing the frequency of SNP 
alleles between large numbers of cases and controls, 
the GWA approach allowed the investigators to detect 
genetic variants with modest phenotypic effects in a 
systematic and unbiased manner, provided that the 
variants had a high frequency in the population. Due to 
the vast amount of genetic variants analyzed in a 
GWAS, a high number of statistical tests are perfor-
med. This leads to a substantial risk of false positives 
owing to multiple testing and a much more stringent 
significance level is required before an association is 
considered statistically significant. Current consensus 
has, based on a simulation study, defined a genome-
wide significance level of P < 5×10-8 to account for 
106 independent genome-wide hypotheses tested in a 
dense GWAS (36). 
 In the spring of 2007, the results from the first wave 
of GWA studies investigating type 2 diabetes genes 
were published, namely the French, deCODE, DGI, 
WTCCC and FUSION studies (37-41). These five 
independent GWA studies were all conducted using a 
two-stage strategy consisting of a GWA screen in an 
initial cohort of unrelated cases and controls followed 
by replication of the most significant findings in addi-
tional patient series. The initial GWAS were followed 
by five smaller GWA studies (42-46). Each of these 
early GWA studies of type 2 diabetes identified 
numerous potential susceptibility variants and nine loci 
were consistently associated with disease risk across 
multiple studies. The nine loci were solute carrier 
family 30, member 8 (SLC30A8), hematopoietically 
expressed homeobox (HHEX), CDK5 regulatory 
subunit-associated protein 1-like 1 (CDKAL1), cyclin-
dependent kinase inhibitor 2A/2B (CDKN2A/B), 
insulin-like growth factor 2 mRNA-binding protein 2 
(IGF2BP2), fat mass- and obesity-associated gene 
(FTO), TCF7L2, KCNJ11 and PPARG, among which 
the latter three had previously been implicated in type 
2 diabetes (see above). 
 The TCF7L2 gene is the most strongly associated 
type 2 diabetes susceptibility gene found to date (29). 
Since its discovery, the association has been replicated 
in a variety of studies in subjects of different ethnici-
ties (47). In the U.K. population, lead SNP has a fre-
quency of 30% and the allelic odds ratio (OR) is 1.36. 
Individuals carrying two risk (T) alleles are at nearly 
twice the risk of type 2 diabetes as are those with none 
(48). TCF7L2 encodes a transcription factor in the 
Wnt-signaling pathway, which induces transcription of 
a number of genes, including proglucagon, in the intes-
tine. Recent studies have shown that there is an increa-
sed expression of TCF7L2 in the islets of pancreas in 
type 2 diabetes, which in turn results in impaired 
glucose-stimulated insulin secretion (49). 
 The French GWA study involved non-obese diabetic 
patients and revealed that a gene encoding a protein 
that transports zinc in the pancreas, SLC30A8, could 
increase the risk of type 2 diabetes (39). Of all the new 
type 2 diabetes genes discovered by the GWAS app-
roach, SLC30A8 is one of the few involving an amino 
acid change – an arginine to tryptophan substitution at 
amino acid 325. Most other genes identified by GWAS 
would not be considered typical candidate genes for 
type 2 diabetes and in most cases the variants are lo-
cated in non-coding regions within or near the gene. 
 In the first wave of GWAS, all studies had sample 
sizes in the range of one to two thousand and were 
therefore to some extent statistically underpowered to 
detect variants with small effect sizes. In recognition 
of this, data from three GWA studies were combined 
by the DIAGRAM consortium. Through meta-analysis 
followed by large-scale replication, six additional type 
2 diabetes susceptibility genes were detected (see 
Table 1) (50). Initial GWAS were mainly performed in 
cases and controls from European populations. For this 
reason studies in other populations were warranted. 
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Table 1.  Genetic regions (variants) associated with type 2 diabetes at genome-wide levels of statistical significance (p < 10-8) 
per June 2012, listed by chromosome. Data in this table are adapted from (4,64,116-118). 
 
Chr Gene region (lead SNP) 
Discovery method (major 
ethnicity) 




Follow-up of signals for T2D from 
GWA scan for FG (European) 
Encodes the prospero-related homeobox 1. Implicated in cell 
proliferation and development. Associated with elevated FG. 
1 NOTCH2 
 (rs10923931) 
GWA meta-analysis (European) Transmembrane receptor implicated in pancreatic organogenesis; 
regulates cell differentiation. 
2 GRB14  (rs3923113) 
GWA meta-analysis (South 
Asians) 
Adaptor protein binding to insulin receptor and insulin-like growth 
factor receptors to inhibit kinase signaling. Associated with 
reduced insulin sensitivity. 
2 BCL11A 
 (rs243021) 
GWA meta-analysis (European) Involved in both B- and T-lymphocyte development and β-cell 
function. Affects insulin response to glucose. 
2 RBMS1  (rs7593730) GWA meta-analysis (European) 
Encodes RNA-binding motif, single-stranded interacting protein 1. 
Implicated in DNA replication, gene transcription, cell cycle 
progression and apoptosis. Unknown diabetogenic mechanism. 
2 GCKR  (rs780094) 
Follow-up of signals for T2D from 
GWA scan for FG (European) 
Glucokinase regulatory protein. Involved in signal transduction, 
glucose transport and sensing. Associated with FG, fasting insulin 
and HOMA-IR. 
2 IRS1  (rs2943641) 
Single GWA study (French, 
European) 
Encodes insulin receptor substrate-1. Associates with reduced 
adiposity and impaired metabolic profile (e.g. visceral to 
subcutaneous fat ratio, IR, dyslipidemia, CVD, adiponectin levels). 
2 THADA  (rs7578597) GWA meta-analysis (European) 
Thyroid adenoma-associated gene. Associates with PPAR; 
Involved in apoptosis. Associated with β-cell dysfunction, lower β-
cell response to GLP-1 and reduced β-cell mass. 
3 ST6GAL1 
 (rs16861329) 
GWA meta-analysis (South 
Asians) 
Enzyme located in Golgi apparatus, involved in post-translational 
modification of cell-surface components by glycosylation. 
3 ADCY5 
 (rs11708067) 
Follow-up of signals for T2D from 
GWA scan for FG (European) 
Encodes adenylate cyclase 5. Involved in signal transduction. 
Associated with elevated FG. 
3 ADAMTS9  (rs4607103) GWA meta-analysis (European) 
Proteolytic enzyme. Affects insulin response to glucose. Primary 
effect on insulin action not driven by obesity. 
3 IGF2BP2  (rs4402960) Single GWA study (European) 
Growth factor (IGF2-mRNA) binding protein. Involved in 
pancreatic development and stimulation of insulin action. 
3 PPARG*  (rs1801282) 
Candidate study; Later 
confirmation by GWA studies 
TRF involved i adipocyte development. TRF receptor for TZDs 
and prostaglandins. Effect on IR. 
4 WFS1*  (rs1801214) 
Candidate study; later validated by 
GWA meta-analysis 
Endoplasmic reticulum transmembrane protein involved in stress 
and β-cell apoptosis. Insulin response. 
5 ZBED3  (rs4457053) GWA meta-analysis (European) 
Encodes an axin-interacting protein activating wnt/beta-catenin 
signaling. Unknown diabetogenic mechanism. 
6 CDKAL1  (rs7754840) 
Single GWA study (Icelandic, 
European) 
Cyklin kinase (CDK5) inhibitor. Involved in cell cycle regulation 
in the β-cell. Insulin response. 
7 KLF14 
 (rs972283) 
GWA meta-analysis (European) 
Basic transcription element-binding protein. "Master switch" 
controlling other genes associated with BMI, insulin, glucose and 
cholesterol. 
7 DGKB  (rs972283) 
Follow-up of signals for T2D from 
GWA scan for FG (European) 
Encodes diacylglycerol kinase beta. Implicated in signal 
transduction. Associated with elevated FG. 
7 GCK* 
 (rs4607517) 
Follow-up of signals for T2D from 
GWA scan for FG (European) 
Encodes the enzyme glucokinase. Involved in signal transduction, 
glucose transport and sensing. Associated with elevated FG and 
HbA1c. 
7 JAZF1  (rs864745) GWA meta-analysis (European) 
Zinc-finger protein. Function as a transcriptional repressor. 
Associated with prostate cancer. Insulin response. 
8 TP53INP1 
 (rs896854) 
GWA meta-analysis (European) 
Encodes the p53-dependent damage-inducible nuclear protein. May 
regulate p53-dependent apoptosis. Unknown diabetogenic 
mechanism. 
8 SLC30A8  (rs13266634) 
Single GWA study (French, 
European) 
β-cell zinc transporter ZnT8. Involved in insulin storage and 




GWA meta-analysis (European) Encodes the transducin-like enhancer of split 4. Unknown 
diabetogenic mechanism. 
9 PTPRD  (rs17584499) Single GWA study (Taiwanese) 
Encodes the tyrosine phosphatase receptor type D protein. 
Associated with increased HOMA-IR and may affect insulin 
signaling on its target cells. 
9 CDKN2A/B  (rs10811661) Single GWA study (European) 
Cyclin-dependent kinase inhibitor and p15/16 tumor suppressor. 
Involved in islet development. Also associated with CVD and 
several cancers. Insulin response. 
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Chr Gene region (lead SNP) 
Discovery method (major 
ethnicity) 
Cellular function and putative intermediary mechanism in 
diabetes 
10 VPS26A  (rs1802295) 
GWA meta-analysis (South 
Asians) 
Multimeric protein involved in transport of proteins from 




GWA meta-analysis (European) Cell cycle kinase, required for S-phase entry. Affects different 
aspects of insulin response to glucose. 
10 HHEX  (rs1111875) 
Single GWA study (French, 
European) 
TRF involved i pancreatic development. Might influence both 
insulin release and insulin sensitivity. 
10 TCF7L2  (rs7903146) 
Linkage study; later confirmation 
by several GWAs (European) 
TRF involved in wnt-signaling. Influencing insulin and glucagon 
secretion. Most important polygene identified for T2D. 
11 ARAP1
b 
 (rs1552224) GWA meta-analysis (European) 
Associated with lower proinsulin levels, as well as lower β-cell 
function (HOMA-B and insulinogenic index). 
11 HMGA2  (rs1531343) GWA meta-analysis (European) 
Oncogene implicated in body size (height). Primary effect on 
insulin action not driven by obesity. 
11 MTNR1B  (rs10830963) 
Follow-up of signals for T2D from 
GWA scan for FG or IS 
Receptor for melatonin. Involved in glucose homeostasis. 





Single GWA study (Japanese, 
Asian, European) 
Encodes the pore-forming alfa subunit of IKaK+ channel. Insulin 
response. 
11 KCNJ11*  (rs5219) 
Candidate study; later confirmation 
by GWAS 




Candidate study; Later 
confirmation by GWA meta-
analysis (European) 
TRF essential for pancreatic β-cell development and function. 
12 TSPAN8  (rs7961581) GWA meta-analysis (European) 




Single GWA study (Chinese) 
Inhibitor of tyrosine kinase signaling. Associated with body fat 
percentage. Homologs inhibit insulin receptor-transduced MAPK 
signaling. Regulates development of pancreas. 
15 AP3S2 
 (rs2028299) 
GWA meta-analysis (South 
Asians) 
Clathrin-associated adaptor complex expressed in adipocytes and 
pancreatic islets. Involved in vesicle transport and sorting. 
Unknown diabetogenic mechanism 
15 HMG20A 
 (rs7178572) 
GWA meta-analysis (South 
Asians) 
High mobility group non-histone chromosomal protein influencing 
histone methylation. Involved in neuronal development. Unknown 
diabetogenic mechanism. 
15 C2CD4A  (rs11071657) Single GWA study (Japanese) 
Nuclear calcium-dependent domain-containing protein. Impairs 
glucose-stimulated insulin response. Associated with levels of 
fasting glucose and proinsulin. 
15 ZFAND6 
 (rs11634397) 









Single GWA study (British, 
European) 




Single GWA study (Taiwanese) Encodes a serine racemase protein. May play a role in regulation of 
insulin and glucagon secretion. 
17 HNF1B*  (rs757210) Candidate study 
TRF involved in development of the kidney, pancreas, liver, and 
Mullerian duct. Implicated in MODY and renal cyst. Associated 
with prostate cancer. 
20 HNF4A*  (rs4812829) 
Candidate study; Later replicated 
by GWA meta-analysis (South 
Asians) 
Nuclear TRF expressed in liver. Regulates transcription of several 
genes, e.g. HNF1A. Elevated hepatic glucose production. Defective 
pancreatic β-cell function and impaired insulin secretion. 
X DUSP9  (rs5945326) GWA meta-analysis (European) 
MAP kinase phosphatase. Decreased insulin release for male risk 
allele carriers. Up-regulated during adipocyte differentiation. 
Involved in insulin signaling and stress induced IR. 
All loci have shown genome-wide statistical significance (p ≤10-8). For many of the loci several SNPs associate with type 2 diabetes, but only 
one (in some cases two) SNPs are listed. Abbreviations: Chr: chromosome; CVD: cardiovascular disease; FG: fasting glucose; GI: 
gastrointestinal; IR: insulin resistance; IS: insulin secretion; T2D: type 2 diabetes; TRF: transcription factor; TZD: thiazolidinediones. aGWA 
signal re-annotated from CHCHD9 to TLE4. bFormerly known as CENTD2. cThese SNPs are in low LD in Europeans (r2 = 0.01), thus they 
most likely represent two independent association signals. *Genes also implicated in MODY, other monogenic forms of diabetes or rare 
genetic syndromes. 
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The first GWAS performed in Asian subjects with type 
2 diabetes discovered a new gene, KCNQ1, which later 
has been confirmed also in European subjects (51,52). 
Notably, most type 2 diabetes variants have been shown 
to have an impact on pancreatic β-cell function with a 
primary effect on insulin secretion rather than on insu-
lin action (53). A GWAS performed in French and Da-
nish subjects revealed, however, a variant in the IRS1 
gene, which together with PPARG belongs to the very 
few type 2 diabetes loci that display a diabetogenic po-
tential by affecting peripheral insulin sensitivity (54). 
 The GWA approach has further demonstrated that 
genetic studies of glycemic traits can identify type 2 
diabetes risk loci. GWAS for fasting glucose or insulin 
secretion revealed from 2008 to 2010 a whole new set 
of type 2 diabetes susceptibility loci. The melatonin-
receptor gene (MTNR1B), which highlights the link 
between circadian and metabolic regulation (55), was 
found to be associated with levels of fasting glucose 
and risk of type 2 diabetes (56-58). Follow-up signals 
of a fourth GWA scan for fasting glucose identified, in 
addition to MTNR1B, five other loci associated with 
type 2 diabetes (59). Recently, several studies have 
reported even larger meta-analyses of GWA data from 
both European and Asian ethnic groups, leading to the 
identification of several new loci for type 2 diabetes, 
including HNF1A and HNF4A (60-62). The confirma-
tion of common variant associations at HNF1A and 
HNF4A added two new loci to those known to harbor 
both rare mutations causing monogenic forms of 
diabetes and common variants predisposing to multi-
factorial diabetes. The number is now seven, the others 
being PPARG, KCNJ11, WFS1, HNF1B and GCK. 
 In summary, GWAS have, by establishing large 
research consortia, performing meta-analyses, using 
intermediary diabetes phenotypes (e.g. fasting glucose) 
and applying study samples of different ethnicities, 
delivered a whole set of new susceptibility loci for 
type 2 diabetes over the last five years, now counting 
over 50 loci (60,63). The validated type 2 diabetes 
susceptibility loci along with their discovery method, 
cellular function and putative intermediary mechanism 
in diabetes are summarized in Table 1. The most 
recently reported type 2 diabetes susceptibility regions 
are individually only associated with a marginally 
increased risk for diabetes (odds ratio < 1.1), and can 
together explain only ~10% of the heritability seen for 
type 2 diabetes (64). Therefore, at present, the known 
type 2 diabetes variants do not add much extra infor-
mation compared to clinical risk factors when it comes 




NORWEGIAN STUDIES AND THEIR 
CONTRIBUTION 
 
The most frequent forms of monogenic diabetes (see 
article by Søvik et al. in this issue of the Norwegian 
Journal of Epidemiology) are caused by rare mutations 
in the genes HNF1A, GCK, HNF4A and HNF1B (66-
68). Naturally, common variants in these genes would 
be plausible candidates involved in glucose homeosta-
sis and metabolism, including type 2 diabetes. Some, 
but not all, studies found an association between com-
mon variants near the HNF4A P2 promoter and type 2 
diabetes. In an attempt to address these inconsisten-
cies, Johansson et al. (69) investigated HNF4A SNPs 
in a large population-based sample of individuals with 
type 2 diabetes and control subjects from the Nord-
Trøndelag Health Studies and included a meta-analysis 
of published studies. The results suggested that varia-
tion in the HNF4A region is associated with type 2 
diabetes in Scandinavians, highlighting the importance 
of exploring small genetic effects in large, homogen-
ous populations. 
 A further study conducted by Thorsby et al. (70) 
studied the impact of four candidate polymorphisms in 
the three well-known type 2 diabetes susceptibility 
genes TCF7L2, PPARG and KCNJ11 on traditional risk 
factors for type 2 diabetes in a sample from HUNT, 
using both cross-sectional and prospective design. The 
two investigated risk alleles of the TCF7L2 gene were 
strongly associated with type 2 diabetes, even after 
controlling for traditional risk factors. These risk 
alleles were associated with indices of reduced beta-
cell function. The population attributable risks for 
diabetes with TCF7L2 risk alleles were 15% and with 
diabetes in a first-degree relative 31%. 
 The GWAS wave provided substantial support for 
several new type 2 diabetes susceptibility variants. 
However, these studies were mainly performed in care-
fully selected cases (sometimes the extremes of the 
phenotype) and controls. To get a better estimate of the 
true effects conferred by these susceptibility loci, Her-
tel et al. (71) used a completely unselected population 
of type 2 diabetic persons and controls from the 
HUNT2 Survey. They confirmed the association with 
type 2 diabetes for three SNPs in or near the genes 
CDKN2B, FTO and SLC30A8, and observed a 
borderline significant association for the variant near 
IGF2BP2. The size effects that were observed in this 
study are close to the estimates from the previous 
studies, indicating that the design of the first GWAS 
round seems to pinpoint risk-alleles that show gene-
rality, at least in other Northern European populations. 
 In the spring of 2007, several independent GWAS 
papers reported a strong correlation between body 
mass index and SNPs in the human FTO gene (38,72-
74). This association was initially seen in a study of 
type 2 diabetes. The diabetogenic effect, however, 
proved to be mediated through adiposity. Common 
variants in the first FTO intron define a risk allele pre-
disposing to both childhood and adult obesity, where 
homozygotes for the risk allele weigh approximately 3 
kilograms more and having a 1.67-fold increased risk 
of obesity compared to homozygotes for the protective 
allele (73). These findings have been extensively re-
produced and the effect is fairly consistent throughout 
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different study populations (reviewed in (75)). The 
FTO risk variants have also shown association with 
obesity-related conditions and diseases such as the me-
tabolic syndrome, polycystic ovary syndrome (PCOS), 
and type 2 diabetes (76-78). However, in most of the 
studies reported, these effects appear to be secondary 
to weight increase since the associations are attenuated 
or completely abolished after adjusting for BMI (78). 
 In our first study using samples from HUNT (71), 
we replicated the association for the same FTO variant 
(rs9939609), both with regard to BMI and type 2 dia-
betes. Interestingly, the association between rs9939609 
and type 2 diabetes and BMI remained significant after 
adjustment for BMI and diabetes status, respectively. 
It is also noteworthy that rs9939609 demonstrated a 
strong association with triacylglycerol levels, which 
was not abolished after correcting for diabetes status. 
Thus, our data suggested that the relation between 
FTO and BMI/diabetes is more complex than initially 
thought. 
 We therefore initiated a Nordic collaborative pro-
ject with two Swedish research groups having access 
to both extensive clinical and genetic data from the 
Malmö Preventive Project (MPP) and Malmö Diet and 
Cancer (MDC) cohorts. Through this collaboration we 
aimed to investigate whether a variant in FTO affects 
type 2 diabetes risk entirely through its effect on BMI 
and how FTO influences BMI across adult life span in 
41,504 subjects from the Scandinavian HUNT, MDC 
and MPP studies. In one of the largest studies to date 
investigating the effect of FTO sequence variants on 
type 2 diabetes and BMI, we demonstrated that FTO 
does not mediate type 2 diabetes risk entirely through 
its influence on BMI (79). In an attempt to capture the 
complex relationship between FTO, BMI, and type 2 
diabetes during the life course, we also performed an 
analysis on incident type 2 diabetes in over 20,000 
non-diabetic individuals followed up for over 10 years. 
Over 3,000 developed type 2 diabetes during follow-
up, and the FTO variant was strongly associated with 
the incident risk of type 2 diabetes. The results re-
mained similar when we controlled for BMI at base-
line (before diabetes was diagnosed), ΔBMI, or waist 
circumference and/or waist-to-hip ratio as covariates in 
the regression analyses. None of the covariates alone 
or in combination with BMI changed our results 
notably: FTO still conferred an increased risk for type 
2 diabetes. This study supports that FTO not only is an 
obesity gene, but also a type 2 diabetes susceptibility 
gene.	  
 The meta-analysis of the FTO-associated allele-
wise effect on BMI using cross-sectional data from the 
HUNT, MPP and MDC studies confirmed the strong 
effect of the FTO SNP on BMI (0.28 kg/m2 per risk 
allele, P= 2.0×10−26), with no significant heterogeneity 
in the effect sizes for the risk allele between different 
adult age groups. Interestingly, using longitudinal data 
from the HUNT and MPP studies, we found no 
differences in change of BMI over time according to 
rs9939609 risk allele status. Hence, our results indicate 
that the additional weight gain as a result of the FTO 
risk variant seems to occur relatively early in life, most 
likely before adulthood, and the relative BMI diffe-
rence remains stable thereafter (79). 
 After the identification of a disease-associated 
region by GWAS, comprehensive studies of sequence 
variation in the region are essential to identify the full 
set of variants that might explain the association 
signal. This is due to the fact that a GWAS is neither a 
candidate-gene approach nor directly intended to detect 
causative variants. Non-coding variants at human 
chromosome 9p21 near CDKN2A and CDKN2B have 
repeatedly been associated with type 2 diabetes (37, 
38,41,50), myocardial infarction (80-82), aneurysm 
(83), stroke (84) and at least five types of cancers (85-
90). Hence, this region appears as one of the most 
interesting regions to emerge from the first-generation 
of GWAS. In a recently submitted paper (91) we app-
lied a genetic fin-mapping approach by assessing 19 
SNPs tagging a 138-kb region on chromosome 9p21 
for association with type 2 diabetes, stroke, myocardial 
infarction, angina pectoris, and coronary heart disease. 
Through single point and haplotype analysis, we found 
evidence for only one common type 2 diabetes risk 
haplotype upstream of the CDKN2B gene region. Fur-
thermore, we confirmed the associations for SNPs in 
the 9p21 region with MI, angina pectoris and coronary 
heart disease. Despite their close proximity, there seems 
to be no apparent overlap between the cardiovascular 
disease and type 2 diabetes risk regions. Theories with 
reference to the disease mechanism mediated by the 
causative risk variants of the 9p21 interval have 
increased in numbers during the last years. However, 
since most of them still remain to be explored, the 
exact nature of the causative variants and the target 
proteins or genes is still elusive. 
 As previously mentioned, GWAS meta-analyses, 
establishment of large consortia, examination of 
intermediary diabetes phenotypes and study samples of 
different ethnicities, have greatly extended the number 
of known type 2 diabetes risk loci. Also several Nor-
wegian scientists have through the last five years con-
tributed in large multi-center consortia (DIAGRAM, 
MAGIC, GIANT) with their experience and with 
samples from the HUNT Survey. Genome-wide ana-
lyses and meta-analyses of these data have revealed 
several novel type 2 diabetes susceptibility loci and the 
results are consistent with a long tail of additional 
common variant loci explaining much of the variation 
in susceptibility to type 2 diabetes (50,62,92-98). 
 Definition and accuracy of the phenotype is one of 
the key issues in designing any genetic study. To in-
crease the chance of finding relevant susceptibility 
genes for complex diseases, one may have to look 
more narrowly and start dissecting them according to 
their pathophysiology or clinical characteristics. In 
contrast to genome-wide searches, genetic analysis of 
an intermediate or low-level phenotype is eased by 
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greater proximity to the genetic variant, thus reducing 
the effects of other factors surrounding and possibly 
influencing the effect of individual genes (99). Poor 
glucose control (expressed as high HbA1c) is a well-
known risk factor for long-term diabetic complications 
and has for a long time been recognized as an interes-
ting intermediate phenotype in relation to diabetes. 
There is variability in glycemic control both between 
and within individuals, and HbA1c have a heritability 
estimate that makes it a phenotype suited for genetic 
analysis (100,101). We have evaluated whether four 
novel SNPs (from the SORCS1, BNC2, GSC and 
WDR72 genes) reported to affect HbA1c levels in sub-
jects with type 1 diabetes (102) had an effect on glyce-
mia in a type 2 diabetes cohort (103). We observed 
allele frequencies similar to the frequencies reported in 
individuals with type 1 diabetes. However, in the indi-
vidual SNP analysis, no significant associations with 
HbA1c or glucose levels were found for the analyzed 
variants. Although the observed effects were non-
significant and of much smaller magnitude than pre-
viously reported in type 1 diabetes, the SORCS1 risk 
variant showed a direction consistent with increased 
HbA1c and glucose levels, with an observed effect of 
0.11% and 0.13 mmol/l increase per risk allele for 
HbA1c and glucose, respectively. In contrast, the 
WDR72 risk variant showed a borderline association 
with reduced HbA1c levels, and direction consistent 
with decreased glucose levels. When we included all 
four variants in a combined genetic score model, we 
observed no evidence for a relationship between in-
creasing number of risk alleles and increasing HbA1c 
or glucose levels. Each additional risk allele demon-
strated an increase in HbA1c of approximately 0.04% 
(103). 
 The different pathophysiology between type 1 and 
type 2 diabetes could be one explanation why our 
results did not support that the four investigated loci 
are genetic susceptibility factors for glycemic control 
in type 2 diabetes. In the future, it will be important to 
expand the study of genetic influences on HbA1c to 
pre-diabetic and diabetic populations, even though the 
confounding effects of treatment might obscure any 
role of these polymorphisms in the diabetic population. 
Initiatives dissecting the genetic influences of HbA1c 
levels will be important not only to better understand 
the genetic and biologic determinants of HbA1c varia-
tion in the general population better, but it could also 
be important in the present initiatives to use HbA1c as a 
diagnostic tool for diabetes (104,105). 
 It has been discussed whether latent autoimmune 
diabetes of adults (LADA) is a mild form of type 1 
diabetes or a distinct etiological entity. Both clinical 
and genetic studies have, however, shown that the 
etiology of LADA resembles partly type 1 and partly 
type 2 diabetes (for more information about LADA see 
article by S. Carlsson et al. in this issue). Pettersen et 
al. (106) tested for association of known type 1 and 
type 2 diabetes susceptibility genes in LADA subjects 
assembled from the HUNT survey, and analyzed rela-
tionships to a marker of autoimmune activity (titers of 
anti-GAD) and a phenotypic risk factor of type 2 dia-
betes (BMI). The majority of the strongly associated 
HLA haplotypes for type 1 diabetes were significantly 
associated with LADA in general, but mainly with 
high anti-GAD LADA patients. Two distinct HLA 
haplotypes were associated only with LADA and 
mainly in low anti-GAD LADA patients. There were 
no associations of non-HLA type 1 diabetes loci with 
LADA. Of type 2 diabetes-associated genes, the 
variant rs7961581 near TSPAN8 and the obesity-linked 
variant rs8050136 in FTO were associated with LADA 
in general, but mainly in low anti-GAD LADA 
patients. This study demonstrated that the genetic 
heterogeneity in LADA is linked to various degrees of 
autoimmune activity and may be partly distinct from 
both type 1 and type 2 diabetes. 
 Several genes implicated in MODY has been 
validated as type 2 diabetes genes through GWAS (see 
Table 1). Mutations in the HNF1A gene are the most 
common cause of MODY, and there is a substantial 
variation in the age at diabetes diagnosis, even within 
families where diabetes is caused by the same muta-
tion. In a recent study using data from two study cen-
ters (Exeter, UK and the Norwegian MODY registry) 
we therefore investigated the hypothesis that common 
polygenic variants that predispose to type 2 diabetes 
might account for the difference in age at diagnosis in 
HNF1A-MODY (107). In a sample of 410 individuals 
with a known mutation in the HNF1A gene, the effect 
of 15 robustly associated type 2 diabetes variants on 
the age at diagnosis was assessed, both individually 
and in a combined genetic score. We observed that 
each risk variant for type 2 diabetes was found to 
lower the age of MODY onset by 0.35 years, inde-
pendent of other genetic and environmental modifiers. 
Thus, this is one of the first studies to demonstrate that 
clinical characteristics of a monogenic disease (i.e. 
MODY) can be influenced by common variants that 
predispose to the polygenic form of that disease (i.e. 
common type 2 diabetes). There will definitely be 
more examples to come (107,108). 
 
CONCLUDING REMARKS AND FUTURE 
PERSPECTIVES  
The aim of this review was to summarize the present 
status regarding the complex genetic nature and archi-
tecture of type 2 diabetes. By reviewing the interna-
tional literature and recent Norwegian studies it is 
evident that there has been a tremendous progress 
during the last five years regarding the dissection of 
the genetic background of type 2 diabetes as well as of 
diabetes-related phenotypes. Although GWAS have 
provided some new biological insights, only a limited 
amount of the heritable component has been identified 
and it remains a challenge to clarify the functional link 
between associated variants and phenotypic traits. It is, 
nevertheless, crucial to continue to perform in-depth
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Figure 2.  Possibility of identifying genetic variants by risk allele frequency and penetrance (strength of genetic 
effect). Frequency and the effect are essential factors when it comes to the likelihood of detecting genetic variants. 
Most emphasis lies in identifying genetic associations with characteristics shown within the diagonal lines. Future 
research adapting next-generation sequencing strategies will in particular focus on identifying low-frequency variants 
with intermediate penetrance. Modified and redrawn from (109). 
 
 
follow-up studies for these and future susceptibility 
loci in unselected samples of patients and control parti-
cipants, since inclusion criteria such as age of onset, 
family history of the trait or BMI may affect the type 
of loci detected. 
 The current generation of GWAS tags common 
SNPs to some extent adequately, but is less efficient in 
detecting SNPs of lower allele frequency or in techno-
logically difficult genomic regions (109). These limita-
tions have been widely recognized and it now seems 
likely that the genetics of common diseases also in-
volve rare and un-catalogued variants with individual-
ly somewhat stronger effects on risk (Figure 2) (110). 
Recent advances in next-generation sequencing tech-
nologies might facilitate substantial progress here. Both 
exome-sequencing and whole-genome sequencing are 
currently being performed in large samples of different 
ethnicities and will hopefully contribute to identifica-
tion of rare variants involved in type 2 diabetes and 
serve as a reference for other studies. 
 As an example, GWAS have revealed that common 
non-coding variants in the MTNR1B gene increase type 
2 diabetes risk (56,57). Although the strongest associa-
tion signal was highly significant, its contribution to 
type 2 diabetes risk was only modest (OR of ~1.10–
1.15). By performing large-scale exon re-sequencing 
in 7,632 Europeans, including 2,186 individuals with 
type 2 diabetes, Bonnefond et al. (111) identified 40 
non-synonymous variants, including 36 very rare vari-
ants (MAF <0.1%), associated with type 2 diabetes. 
Four of these were very rare with complete loss of me-
latonin binding and signaling capabilities. This study 
establishes a link, both genetically and functionally, 
between the MTNR1B gene and type 2 diabetes risk, 
and further highlights the importance of rare variants 
in health and disease. 
 Another way to identify rare genetic variants with 
expectedly large effects is to study families with some 
accumulation of disease. Genetic variations that cause 
disease will occur with higher frequency in the affec-
ted relatives than in a reference population. Exome-
sequencing will then be an appropriate approach for 
tracking down the gene variations, as recently de-
monstrated for the MITF gene and malignant melano-
ma (112). Sequencing of families with extreme quanti-
tative traits could also be an important next step in the 
dissection of the genetics of type 2 diabetes. 
 Finally, most genetic research has an overall aim of 
translating the findings into progression in clinical care. 
The mechanistic insights generated by gene discovery 
might identify new therapeutic targets and lead to 
novel pharmaceutical and preventative approaches. 
This was shown for those patients who could switch 
from insulin to oral sulfonylureas due to rare mutations 
in KCNJ11 (113,114). Moreover, loss of function va-
riants that reduce the risk for disease may also provide 
hypotheses for new therapeutic strategies, an approach 
used to design cholesterol-lowering drugs based on 
genetic findings in PCSK9 (115). In addition, there is a 
growing belief that individual patterns of genetic pre-
disposition will be valuable in health-care delivery and 
contribute to the development of a more personalized 
medicine. However, the development of personalized 
medicine beyond monogenic diseases requires a more 
complete picture of the genetic predisposition and the 
disease mechanisms. Hopefully, in a few years, large-
scale genome-wide re-sequencing efforts have provided 
a systematic and a more complete description of the 
associations between genome sequence variation and 
major clinical phenotypes like type 2 diabetes. 
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